A Study of Itolizumab (EQ001) to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity in Uncontrolled Asthma: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for A Study of Itolizumab (EQ001) to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity in Uncontrolled Asthma (NCT04007198), a randomized phase 1 study. The primary outcome is Number of Treatment Emergent Adverse Events.

2. Clinical Question

The study asks whether EQ001 can be evaluated for safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity in people with moderate-to-severe uncontrolled asthma. The posted primary outcome is an adverse-event count assessed by Study Day 85. The clinical question is framed around safety and activity, but the registry record does not report results for the pharmacokinetic, pharmacodynamic, or clinical activity outcomes.

The question is therefore best read as an early study assessment of safety and tolerability alongside planned pharmacokinetic, pharmacodynamic, and clinical activity evaluation—not as a definitive estimate of treatment effect. The registry record gives event counts for the three listed arms, but does not report adjusted comparisons, confidence intervals, or statistical tests for this primary outcome.

3. Trial Design

The registry record describes a randomized, double-blind, placebo-controlled study; its masking field specifies quadruple masking. It lists the study model as sequential and identifies the study as Phase 1. The official title calls it a Phase 1b study. The study is described as multi-center and as evaluating safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of EQ001 in moderate-to-severe uncontrolled asthma.

Enrollment is listed as 18. The arms are EQ001 0.8mg/kg, EQ001 1.6mg/kg, and EQ001 Placebo. The posted arm counts are 7.0, 7.0, and 4.0, respectively. The registry record describes the active treatment and placebo regimens as blinded, dose-escalating cohort treatment by subcutaneous injection every two weeks for a total of 5 doses. The detailed sequence of dose escalation, cohort decisions, and allocation procedures is not reported in the registry record.

The study start date is 2019-06-20, the primary completion date is 2021-10-12, and the status is completed. These dates describe the registry record’s study timeline; they do not, by themselves, establish when results were analyzed or made available.

The primary outcome is the number of participants with adverse events, with a timeframe of Study Day 85. The outcome description says the events were treatment-related and assessed with CTCAE v5.0, although the outcome title uses the term treatment-emergent. Secondary outcomes listed include measures of EQ001 serum concentration and exposure, distribution volume, clearance, inflammatory markers, and CD6 receptor expression. The record lists eight secondary outcomes, but results for these outcomes are not reported in the registry record.

The record does not describe the planned sample-size justification, formal statistical analysis plan, or interim analysis procedures. It also does not report additional detail on randomization sequence generation or concealment. These omissions limit how fully the intended design and analysis can be reconstructed.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Before assignment: Cohorts for dose 2.4mg/kg and 3.2mg/kg were not conducted. Data for placebo subjects in cohort for 0.8mg/kg and 1.6mg/kg were pooled in analysis.

Overall Study

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Number of Treatment Emergent Adverse Events, measured over Study Day 85.

The primary outcome is titled Number of Treatment Emergent Adverse Events. Its description defines the measure as the number of participants with treatment-related adverse events assessed using CTCAE v5.0, with assessment through Study Day 85. The unit is participants, and the outcome is a count of people with an event rather than a rate of events or a measure of event severity.

Adverse-event outcomes are used in clinical studies to describe harms observed during treatment and follow-up. Counting participants with at least one event gives a person-level summary: it does not show how many events each participant had, how long events lasted, or whether an event led to treatment discontinuation. Those details are not reported in the registry record for this endpoint.

The distinction between treatment-emergent and treatment-related matters. In general, treatment-emergent describes an event arising or worsening during the specified treatment period, whereas treatment-related indicates an attribution to treatment. Here, the title and definition use different terms; the registry record does not explain that difference. The reported count should therefore be interpreted according to the stated definition, while noting the title-definition mismatch.

The endpoint can describe the observed number of participants meeting that definition in each arm. By itself, it does not establish whether an event was caused by treatment or quantify a comparative effect. The registry record does not report a statistical comparison or uncertainty interval for this primary outcome.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

Statistical interpretation depends on matching the analysis to the outcome, design, and amount of information. The record identifies the primary endpoint as a participant count and lists three arms. It does not report an inferential analysis for that endpoint. The distinctions below explain what common statistical quantities would mean in general; they are not claims that those analyses were conducted for this study.

What does a participant count represent?

A count of participants with an event records how many people met the endpoint definition. Unlike an event total, it does not count repeated events in the same person more than once. In this study, the endpoint description specifies participants with treatment-related adverse events through Study Day 85. The record does not give participant-level event histories, the number of events per person, or event duration. The count therefore offers a limited summary of occurrence, not a full account of the adverse-event experience.

The title-definition mismatch also affects interpretation. “Treatment-emergent” and “treatment-related” are not interchangeable descriptions in general. Treatment-emergent refers to an event occurring or worsening in the relevant period; treatment-related implies an attribution judgment. The registry record states the latter in the endpoint description but does not explain how attribution was determined or how the difference in wording was handled.

What would an arm comparison require?

A comparative analysis would need to define which arms are being compared and how the participant-level outcome is modeled or summarized. Randomization provides a design framework for comparing assigned groups, but a statistical result still needs an estimate and a measure of uncertainty. The posted record gives counts and arm sizes but does not report a comparison estimate, confidence interval, or hypothesis test. Values for a two-arm binary comparison are identified as missing or not estimable.

For a binary outcome, a comparison might be expressed using a difference in proportions or another effect measure. Those measures are not calculated because the registry record does not report them, and no new calculation should be inferred from the counts. A confidence interval, in general, indicates the uncertainty around an estimated effect under a specified method. A p-value, in general, measures how incompatible the observed data are with a stated null model under the analysis assumptions. Neither can be interpreted without a reported analysis and its assumptions.

Why do arm sizes and study scale matter?

Small arm sizes generally make estimates less stable and can yield wide uncertainty intervals. This is a general statistical limitation, not a calculation of the precision for these particular results. The registry record lists arm sizes and an overall enrollment value, but does not report a sample-size justification or a target precision for the primary outcome. It is therefore not possible to determine from the record whether the study was designed to test a particular adverse-event difference or to estimate it to a specified precision.

Rare or serious events can be especially difficult to characterize in a small study. An observed event count is important to report, but a low count does not establish that an event cannot occur, and a count in one arm does not alone establish a difference between treatments. General interpretation should consider the number of participants observed, follow-up, event definitions, and the completeness of event ascertainment. Details about missing safety observations and follow-up completeness are not reported in the registry record.

How should the sample-size illustrations be read?

The registry record’s sample-size assumptions describe planning illustrations based on the observed effect, not the trial’s own design. They specify a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation; the effect to detect is described as a stated fraction of the observed effect. For time-to-event outcomes, the stated convention is a total number of events; for other outcomes, it is participants per arm. These assumptions describe hypothetical planning calculations, not observed power and not evidence that the original trial was planned using those assumptions.

Planning calculations based on an observed effect can be sensitive to the estimate used. In general, an effect estimated from a small study may be imprecise, so a planning illustration should not be mistaken for a reliable forecast of a future study’s requirements. The registry record does not report a sample-size justification for the original study. No numerical planning result is stated in the record information.

What is not available for evaluating the analysis?

The registry record lists no analysis records. It does not report the statistical model, a prespecified contrast, covariate adjustment, handling of repeated or multiple events, or an approach to missing observations. It also does not report whether any interim analyses were planned or performed. These omissions do not show that no such procedures existed; they mean they are not reported in the registry record.

In general, a statistical plan helps readers distinguish planned analyses from post hoc exploration and understand how multiplicity, missing data, and protocol deviations were handled. Without those details, the posted counts can be described, but the analysis choices and robustness of any treatment comparison cannot be evaluated. The results should therefore be read descriptively and within the limits of the record.

10. Exact Estimates for Each Arm

No two-arm comparison is shown for this trial, but each arm's result can still be summarized with exact interval estimates computed from the posted counts. The Clopper-Pearson interval is exact and conservative; the Wilson interval is a common closer-to-nominal alternative; the Bayesian credible interval uses a uniform Beta(1, 1) prior. For small groups the three can differ noticeably.

R code and output

arm    <- c("EQ001 0.8mg/kg", "EQ001 Placebo", "EQ001 1.6mg/kg")
n      <- c(7, 4, 7)
events <- c(6, 1, 7)
for (i in seq_along(n)) {
  ci <- binom.test(events[i], n[i])$conf.int          # Clopper-Pearson exact interval
  cr <- qbeta(c(0.025, 0.975), 1 + events[i], 1 + n[i] - events[i])   # Bayesian, uniform Beta(1,1) prior
  wi <- (function(x, n) { p <- x / n; z <- qnorm(0.975); d <- 1 + z^2 / n
    c((p + z^2 / (2 * n) - z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d, (p + z^2 / (2 * n) + z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d) })(events[i], n[i])
  cat(sprintf("ARM|%s|%d|%d|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f\n", arm[i], n[i], events[i], 100 * events[i] / n[i],
              100 * ci[1], 100 * ci[2], 100 * wi[1], 100 * wi[2], 100 * cr[1], 100 * cr[2]))
}

ARM  EQ001 0.8mg/kg  7  6  85.7  42.1  99.6  48.7  97.4  47.3  96.8
ARM  EQ001 Placebo  4  1  25.0  0.6  80.6  4.6  69.9  5.3  71.6
ARM  EQ001 1.6mg/kg  7  7  100.0  59.0  100.0  64.6  100.0  63.1  99.7

11. Multiplicity, Missing Data and Analysis Populations

The registry record lists one primary outcome and eight secondary outcomes. The secondary outcomes include EQ001 concentration and exposure measures, volume of distribution, clearance, inflammatory markers, and CD6 receptor expression. The study description also includes clinical activity among its aims. Results for these secondary outcomes are not reported in the registry record.

When a study examines multiple outcomes or comparisons, multiplicity can increase the chance of finding at least one apparently unusual result by chance. In general, investigators may address this through a prespecified hierarchy, adjustment method, or clearly labeled exploratory analyses. The statistical plan for multiplicity is not reported in the registry record. The record does not state whether any adjustment was used or which outcomes were intended to support confirmatory conclusions.

The record does not describe how missing data were handled, whether all randomized participants were included in each outcome analysis, or how participants with incomplete follow-up were treated. Analysis populations, including any intention-to-treat or per-protocol population, are not reported in the registry record. Those details matter because exclusions and incomplete observation can affect both the count and its interpretation.

The record lists no analysis records, and comparative values for a two-arm binary outcome are identified as missing or not estimable. This leaves no reported inferential result for the primary endpoint to assess alongside the descriptive counts. The absence of a reported method should not be interpreted as evidence that missingness or multiplicity had no effect; those issues cannot be evaluated from the registry record.

12. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: peripheral artery thrombosis (14.3%).

The serious adverse-event figures are listed by arm. The EQ001 0.8mg/kg group has 0 serious adverse events among 7 at risk; the EQ001 1.6mg/kg group has 1 among 7 at risk; and the placebo group has 0 among 4 at risk. The registry record lists 0 deaths in each group.

The record also names peripheral artery thrombosis as a top serious term and gives 14.3%. It does not report the arm attribution or denominator for that term in the listed information, so the percentage should not be assigned to a particular arm or interpreted as an arm-specific rate.

In general, a serious adverse event is a separate safety classification from the broader count of participants with adverse events. A serious-event count does not describe all adverse events, and the primary endpoint count should not be treated as equivalent to the serious-event count. The record does not provide further detail on severity, timing, relatedness, or outcomes for the serious events.

These are descriptive observations from the registry record. In general, a small number of observed serious events cannot precisely characterize uncommon risks or establish a difference between arms. The record does not report comparative estimates or uncertainty intervals for serious adverse events.

13. What the Result Does, and Does Not, Mean

The posted data describe participants recorded with the primary adverse-event outcome in each arm through Study Day 85. They also list serious adverse events, deaths, and a serious-event term. These are useful descriptions of what the registry record reports, but the counts alone do not quantify a treatment effect or its precision.

The result does not establish that EQ001 caused the recorded events. The endpoint description uses the term treatment-related, but the record does not provide the attribution process or supporting event-level information. Nor does the result establish that treatment did or did not change the chance of an adverse event relative to placebo: no comparative estimate, confidence interval, or statistical test is reported.

The study’s stated aims include safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity. The available results described in the registry record are not a complete account of those aims. Results for the listed secondary outcomes are not reported in the registry record. The record also does not provide the analysis populations, missing-data procedures, or planned statistical methods needed to assess how the results were generated.

In general, a randomized, masked design can support fairer comparisons by limiting some sources of bias, but it does not make a small descriptive count conclusive. Interpretation also depends on follow-up, outcome definitions, completeness of data, and the analysis plan. Those details are not all available in the registry record.

The soundest reading is therefore bounded: the record reports arm-specific counts for the stated endpoint and separate serious-event figures. It does not report enough comparative statistical information to determine the size or precision of differences, and it does not support conclusions about unreported pharmacokinetic, pharmacodynamic, or clinical activity results. The findings should be understood as a limited registry account of an early-phase study, not as a complete evaluation of benefit or risk.

14. Why This Trial Matters Statistically

This trial illustrates a recurring challenge in early clinical research: safety outcomes can be clinically important even when a study is not accompanied by a fully reported comparative analysis. Reporting the number of participants with events gives readers a direct description of observed outcomes. Statistical interpretation, however, also depends on the endpoint definition, arm sizes, follow-up, and the uncertainty around any comparison.

The record is particularly instructive because the primary outcome title refers to treatment-emergent adverse events, while the description defines participants with treatment-related adverse events. This distinction affects what the count is intended to represent. Clear alignment between an outcome’s title, definition, assessment window, and analysis can make results easier to interpret and reproduce.

The study also lists multiple safety, pharmacokinetic, pharmacodynamic, and clinical activity objectives. When several outcomes are considered, readers need to know which analyses were prespecified and how multiplicity was handled. Those methods are not reported in the registry record. Similarly, missing-data handling and analysis populations are not described, limiting evaluation of the results beyond their posted counts.

Finally, the record shows why descriptive event counts should not be mistaken for precise evidence of a treatment difference. General statistical principles call for estimates of uncertainty and a transparent analysis plan, especially when arm sizes are limited and outcomes may be uncommon. The record’s findings can be read as reported safety observations, while the absence of comparative analyses and other outcome results marks important boundaries on what can be concluded.

15. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The principal limitation is the absence of a reported inferential comparison for the primary outcome. The registry record gives arm counts and arm sizes but does not report an effect estimate, confidence interval, or hypothesis test. The record specifically identifies two-arm binary comparison values as missing or not estimable. The magnitude and precision of any difference therefore cannot be evaluated from the posted results.

The primary endpoint wording is not fully consistent: its title says treatment-emergent adverse events, while its description says treatment-related adverse events. The record does not explain whether the definition or title governs interpretation, how relatedness was assessed, or how events were counted beyond the participant-level measure.

Further limitations are the lack of reported analysis populations, missing-data methods, statistical model, multiplicity approach, and sample-size justification. The registry record does not explain the sequential model’s operational details or report whether interim analyses were planned or performed. Results for the listed secondary outcomes are not reported in the registry record.

The serious-event term peripheral artery thrombosis is listed at 14.3%, but its arm attribution and denominator are not reported in the registry record. The serious-event listings do not provide event timing, severity detail, relatedness, or participant-level histories. These omissions limit the context available for interpreting the safety figures.

These limitations concern what can be evaluated from the registry record; they do not establish that unreported analyses or procedures were not conducted. The posted results support descriptive reporting, while conclusions about comparative effects, precision, and the study’s other objectives remain limited.

16. Related Tutorials

17. Related Statistical Calculators

18. Sources

• ClinicalTrials.gov: A Study of Itolizumab (EQ001) to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity in Uncontrolled Asthma — NCT04007198.
• Registry record last updated 2026-06-02; status last verified 2026-05.
• Results first posted 2025-04-18.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

19. Record Summary

NCT04007198 is a completed randomized, double-blind, placebo-controlled study of EQ001 in moderate-to-severe uncontrolled asthma. The registry record lists Phase 1, while the official title describes a Phase 1b study. Enrollment is listed as 18. The study start date is 2019-06-20 and the primary completion date is 2021-10-12.

The three arms are EQ001 0.8mg/kg, EQ001 1.6mg/kg, and EQ001 Placebo. The primary outcome is a participant count through Study Day 85. Posted counts are 6.0, 7.0, and 1.0, respectively. Serious adverse events are listed separately, as are deaths and a serious-event term.

The registry record does not report a comparative analysis for the primary outcome, results for the listed secondary outcomes, or details of the statistical plan, missing-data handling, or analysis populations. The available findings are therefore descriptive and do not establish the magnitude or precision of a treatment difference.